Search | Clinical Trials Finder

Conditions: Hair Thinning
Interventions: Nutrafol Supplement Capsules, Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: letrozole, gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, breast biopsy, diagnostic laboratory biomarker analysis, pharmacological study; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 3
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Conditions: Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Interventions: Vaginal Lubrication Ring for Vaginal Dryness; Device
Lead sponsor: J3 Bioscience, Inc.; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: letrozole, Blood Collection, biopsy/lumpectomy/mastectomy; Drug · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 5
States / cities: Atlanta, Georgia • Tulsa, Oklahoma • Pittsburgh, Pennsylvania + 1 more

Conditions: Breast Cancer, Cancer of the Breast, Breast Neoplasm
Interventions: Letrozole (Femara), Letrozole; Avastin; Other · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Post-Menopausal Osteoporosis
Interventions: ibandronate [Bonviva/Boniva]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Female only
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Loma Linda, California • Lakewood, Colorado • Omaha, Nebraska + 2 more

Conditions: Menopause
Interventions: TSEC (Tissue-selective estrogen complexes), Placebo; Drug · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 50 Years to 60 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Osteoporosis
Interventions: Not listed
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Stress Urinary Incontinence
Interventions: Vesair Balloon; Device
Lead sponsor: Solace Therapeutics, Inc.; Industry
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Arlington Heights, Illinois • Shreveport, Louisiana • Hanover, Maryland + 5 more

Conditions: Breast Cancer
Interventions: Technology-Based Physical Activity Promotion, Pedometer Intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
Interventions: SDX-7320; Drug
Lead sponsor: SynDevRx, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Scottsdale, Arizona • Los Angeles, California • Nashville, Tennessee

Conditions: Cognitive Impairments, RRSO
Interventions: lisdexamfetamine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Amcenestrant (SAR439859), Letrozole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • Fort Wayne, Indiana + 3 more

Conditions: Cardiovascular Diseases, Overweight, Obesity, Hypertension, Cholesterol, Diabetes Mellitus, Prediabetic State, Menopause, Cognitive Behavioral Therapy, Primary Health Care, Stress Disorders, Post-Traumatic, Prevention, Implementation Science, Quality Improvement
Interventions: EBQI Booster (EBQI/B), EBQI Booster + External Facilitation (EBQI/B+EF); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Breast Cancer, Endometrial Cancer
Interventions: Genistein, Placebo; Dietary Supplement
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: Bosutinib, Letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Whittier, California • Joliet, Illinois • Niles, Illinois + 2 more

Conditions: Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
Interventions: JDS-HF3.0; Dietary Supplement
Lead sponsor: Bonafide Health; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Breast Cancer
Interventions: Physical Evaluation, Dual-energy X-ray absorptiometry scans, Trabecular Bone Score; Other · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cancer
Interventions: fatigue assessment and management, management of therapy complications, psychosocial assessment and care; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 9
States / cities: Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more

Conditions: Osteoporosis, Osteoporosis, Postmenopausal
Interventions: Parathyroid Hormone-related Protein, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Postmenopausal Women
Interventions: KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Osteoporosis, Post-Menopausal
Interventions: Raloxifene, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 2
States / cities: Indianapolis, Indiana • Omaha, Nebraska

Conditions: Breast Cancer
Interventions: Letrozole, Placebo, Taselisib; Drug · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more

Search by objective public record fields.

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva

Raising Insulin Sensitivity in Post Menopause

Role of T-cells in Post-Menopausal Osteoporosis

Vesair Balloon Confirmatory Trial (VECTOR)

Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Enhancing Mental and Physical Health of Women Veterans 3.0

Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors

Long Term Effects of Raloxifene Treatment on Bone Quality

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)